Discontinued — last reported Q3 '24
Thermo Fisher Scientific D&A decreased by 12.6% to $449M in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 23.1%, from $584M to $449M.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ3 2024Nov 1, 2024
Metric ID:
depreciation_and_amortizationHistorical Data
11 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $449M | $423M | $609M | $600M | $594M | $606M | $585M | $584M | $551M | $514M | $449M |
| QoQ Change | — | -5.8% | +44.0% | -1.5% | -1.0% | +2.0% | -3.5% | -0.2% | -5.7% | -6.7% | -12.6% |
| YoY Change | — | — | — | +33.6% | +40.4% | -0.5% | -2.5% | -1.7% | -9.1% | -12.1% | -23.1% |
Range$423M – $609M
CAGR+0.0%
Avg YoY Growth+3.1%
Median YoY Growth-2.1%
Current Streak5 quarters decline
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Analytical Instruments | $277M | $290M | $304M | $276M | $256M | $227M | $292M | $306M |
| Laboratory Products and Biopharma Services | — | — | — | — | — | $227M | $292M | $306M |
| Laboratory Productsand Services | $277M | $290M | $304M | $276M | $256M | $227M | $292M | $306M |
| Life Sciences Solutions | $277M | $290M | $304M | $276M | $256M | $227M | $292M | $306M |
| Specialty Diagnostics | $277M | $290M | $304M | $276M | $256M | $227M | $292M | $306M |
| Total | $514M | $449M | — | — | — | — | — | — |
Laboratory Productsand Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's d&a?
- Thermo Fisher Scientific (TMO) reported d&a of $449M in Q3 2024.
- How has Thermo Fisher Scientific's d&a changed year-over-year?
- Thermo Fisher Scientific's d&a decreased by 23.1% year-over-year, from $584M to $449M.